The global immuno-oncology assay market accounted for $2,769.50 million in 2018, and is expected to reach $ 6,179.20 million by 2026, growing at a CAGR of 10.6% from 2019 to 2026. Immuno-oncology assays are widely being used for the diagnosis of different types of cancer. In addition, this assay provides a gain in assay dynamic range, and is used to amplify multiple targets in a polymerase chain reaction (PCR) and collect more information from minute quantities of proteins or other analytes in lesser time. Immuno-oncology assays find its application in pathogen identification, mutation analysis, RNA detection, gene detection analysis, linkage analysis, and others.
The global immuno-oncology assay market is witnessing significant growth, owing to increase in R&D activities in the pharmaceuticals for the treatment of cancer. These assays are used in clinical trials, as they decrease the cost of research & manual labor and an increase the efficiency of experiments and therapies. Moreover, they allow to understand a compound’s response precisely intended to mimic the tumor microenvironment. Optimized cell-based assays deliver crucial information to confirm the efficiency of a drug or a compound in simple and progressively complex co-culture assays. In addition, they offer easier & faster analysis of cancer, and are automated as compared to conventional methods, thus fueling the market growth. However, high capital investment and dearth of skilled labors are the major factors that hinder the market growth. On the contrary, technological development of automated immuno-oncology assay is anticipated to create lucrative opportunities for market expansion in the near future.
The global immuno-oncology assay market is segmented into product, technology, indication, application, and region. On the basis of product, the market is bifurcated into consumables and software. By technology, it is classified into immunoassay, polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others. As per indication, it is divided into colorectal cancer, lung cancer, melanoma, bladder cancer, and others. The applications covered in the study include clinical diagnostics and research. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Product
By Technology
By Indication
By Application
By Region
KEY MARKET PLAYERS
The other players in the value chain include (profiles not included in the report)
The global immuno-oncology assay market is segmented into product, technology, indication, application, and region. On the basis of product, the market is bifurcated into consumables and software. By technology, it is classified into immunoassay, polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others. As per indication, it is divided into colorectal cancer, lung cancer, melanoma, bladder cancer, and others. The applications covered in the study include clinical diagnostics and research. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global immune-oncology assay market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided.
- A comprehensive quantitative analysis of the industry is provided from 2018 to 2025to assist stakeholders to capitalize on the prevailing market opportunities.
- An extensive analysis of the key segments of the industry helps to understand the global trends in the immune-oncology assay market.
- Key players and their strategies are provided to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
By Product
- Consumables
- Software
By Technology
- Immunoassay
- PCR
- NGS
- Flow Cytometry
- Others
By Indication
- Colorectal Cancer
- Lung Cancer
- Melanoma
- Bladder Cancer
- Others
By Application
- Clinical Diagnostics
- Research
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Saudi Arabia
- South Africa
- Brazil
- Rest of LAMEA
KEY MARKET PLAYERS
- Luminex Corporation
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- Becton, Dickinson and Company
- Abcam PLC
- Seegene Inc.
- Randox Laboratories Ltd.
The other players in the value chain include (profiles not included in the report)
- Merck KGaA
- Agilent Technologies
- Quanterix
- Olink
- Sysmex Corporation
- Siemens Healthcare GmbH
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT
CHAPTER 5: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY
CHAPTER 6: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION
CHAPTER 7: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION
CHAPTER 8: IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION
CHAPTER 9: COMPANY PROFILES
Executive Summary
According to this report titled, 'Immuno-oncology assay Market by Product, Application, Indication, and Technology: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global immuno-oncology assays market size accounted for $2,769 million in 2018, and is expected to reach 6,179 million by 2026, growing at a CAGR of 10.6% from 2019 to 2026. North America was the highest revenue contributor in 2018 and is anticipated to continue this trend throughout the forecast period.Immuno-oncology is an area of scientific research involved in investigating that how immune system can fight cancers. It is a procedure used to find out the potential of the immune system to fight against cancer cells. Further, cancer has become one the most frequent causes of mortality in western industrialized countries. Immune oncological approaches are serving to determine new potent curative cancer treatment that could possibly even lead to the eradication of most types of cancer.
The major factors which drive the growth of this market include significant rise in cancer incidence across the globe and an increase in R&D activities for the developing cancer treatments. However, dearth of skilled labor and high capital investment are anticipated to restrain the immune-oncology assay market growth during the forecast period. On the contrary, increased focus on developing automated immuno-oncology assay is anticipated to create lucrative opportunities in the near future.
The global immuno-oncology assay market in this report is studied based on product, technology, indication, application, and region. On the basis of product, the market is divided into consumables and software. By technology, the market is classified into immunoassay, polymerase chain reaction (PCR), next generation sequencing (NGS), flow cytometry and others. Based on indication, it is bifurcated into colorectal cancer, lung cancer, melanoma, bladder cancer and others. By application it is segmented into clinical diagnostics, research. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Based on product, the consumables segment held the largest share of 60% in 2018 and is anticipated to remain the same during the forecast period, due to the usage of several kinds of reagents, kits, instruments for performing the assays. However, software segment is anticipated to grow at the fastest rate during the forecast period.
By technology, the PCR segment accounted for the majority of immuno-oncology assay market share and is anticipated to continue its dominance during the forecast period. This is attributed to the wide usage of PCR while performing oncology diagnosis and research. In addition, technological advancements in PCR technology such as advent of real time PCR further contributes to the immuno-oncology assay market growth.
According to Onkar Sumant, Manager, Healthcare, “Significant increase in R&D pertaining to the development of novel drugs and biomarkers across the globe drives the market growth for immuno-oncology assays market .Moreover, surge in incidence of cancer across the globe is a key factor that propels the growth of the global market.”
KEY FINDINGS OF THE STUDY
- Dependingon product, consumables was the leading segment of the global immune-oncology assay market in 2018, and is projected to grow at a CAGR of 10.2% during the forecast period.
- North America accounted for the share of 42% of the market in 2018, and is projected to grow at a CAGR of 10.1%.
- By technology, the PCR segment accounted for the largest market share of 60% in 2018.
- As per application, the research segment held the highest market share in 2018, and is expected to lead the market during the analysis period.
Region wise, North America was the highest revenue generator with a share of 44% in 2018. This is attributed to increase in expenditure in R&D, presence of well-established healthcare infrastructure, and higher demand for technically advanced devices for research. However, the Asia-Pacific region is projected to grow with the highest CAGR of 12.2% during the analysis period, owing to surge in healthcare expenditure, increase in per capita income, and improvement in healthcare infrastructure.
The major players operating in the global immuno-oncology assays market are Agilent Technologies, F. Hoffmann-La Roche, HTG Molecular Diagnostics, Illumina, Merck, NanoString Technologies, PerkinElmer, Qiagen, Sartorius, and Thermo Fisher Scientific. These players adopted product launch, collaboration, and merger & acquisition as their key developmental strategies to strengthen their foothold in the market.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
